{
  "id": 19218571,
  "title": "CytomX at guggenheim healthcare conference: varseta-m gains traction",
  "url": "https://urgent.news/2026/11/09/cytomx-at-guggenheim-healthcare-conference-varseta-m-gains-traction",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T21:03:18.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/cytomx-at-guggenheim-healthcare-conference-varsetam-gains-traction-93CH-5013164"
  },
  "original_language": "en",
  "account": null,
  "summary": "CytomX Therapeutics presented its progress on Varseta-M, its masked antibody-drug conjugate targeting EpCAM in colorectal cancer, at the Guggenheim Healthcare Innovation Conference on 09 November 2026. The drug demonstrated response rates of 20% to 30% and progression-free survival of 6 to 7 months in fourth-line or later patients, significantly outperforming current standard options such as fruquintinib and regorafenib, which typically produce response rates of 1% to 2% and progression-free survival of about 3 months. Varseta-M's safety profile was also highlighted, with no acute pancreatitis, no pancreatic enzyme elevation, no interstitial lung disease, and lower rates of severe diarrhea after dose changes. The company is considering two phase III paths for Varseta-M: a fourth-line study against fruquintinib or regorafenib, or a third-line study against bevacizumab plus LONSURF.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}